Compass Therapeutics (CMPX) Expected to Announce Quarterly Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:00 AM ET.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $5.89 on Tuesday. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The firm has a market capitalization of $1.05 billion, a PE ratio of -13.09 and a beta of 1.46. The business’s 50 day moving average price is $5.79 and its 200-day moving average price is $4.65.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Raymond James Financial reaffirmed an “outperform” rating and set a $9.00 target price on shares of Compass Therapeutics in a research note on Tuesday, January 6th. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Craig Hallum started coverage on shares of Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a report on Wednesday, February 4th. Finally, William Blair initiated coverage on Compass Therapeutics in a research report on Monday, January 5th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.36.

Institutional Trading of Compass Therapeutics

Hedge funds have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Compass Therapeutics during the 1st quarter valued at approximately $34,000. Creative Planning acquired a new stake in Compass Therapeutics during the second quarter worth $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the second quarter valued at $84,000. Invesco Ltd. raised its position in Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after purchasing an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after purchasing an additional 449,868 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.